Rockefeller Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $48M | Buy |
1,993,256
+8,430
| +0.4% | +$221K | 0.07% | 248 |
|
|
2026
Q1 | $55.7M | Buy |
1,984,826
+142,551
| +8% | +$3.8M | 0.1% | 192 |
|
|
2025
Q4 | $45.9M | Buy |
1,842,275
+392,913
| +27% | +$9.91M | 0.08% | 222 |
|
|
2025
Q3 | $36.9M | Buy |
1,449,362
+110,635
| +8% | +$2.73M | 0.07% | 247 |
|
|
2025
Q2 | $32.5M | Sell |
1,338,727
-371,100
| -22% | -$8.65M | 0.07% | 259 |
|
|
2025
Q1 | $43.3M | Buy |
1,709,827
+44,423
| +3% | +$1.16M | 0.11% | 191 |
|
|
2024
Q4 | $44.2M | Buy |
1,665,404
+35,315
| +2% | +$958K | 0.11% | 175 |
|
|
2024
Q3 | $47.2M | Buy |
1,630,089
+32,524
| +2% | +$949K | 0.13% | 168 |
|
|
2024
Q2 | $44.7M | Sell |
1,597,565
-133,551
| -8% | -$3.68M | 0.13% | 164 |
|
|
2024
Q1 | $48M | Sell |
1,731,116
-517,866
| -23% | -$14.4M | 0.14% | 153 |
|
|
2023
Q4 | $64.7M | Buy |
2,248,982
+43,846
| +2% | +$1.33M | 0.22% | 113 |
|
|
2023
Q3 | $73.1M | Buy |
2,205,136
+121,124
| +6% | +$4.28M | 0.28% | 83 |
|
|
2023
Q2 | $76.4M | Buy |
2,084,012
+83,329
| +4% | +$3.24M | 0.3% | 76 |
|
|
2023
Q1 | $81.6M | Sell |
2,000,683
-59,831
| -3% | -$2.58M | 0.35% | 68 |
|
|
2022
Q4 | $106M | Buy |
2,060,514
+547,851
| +36% | +$26.3M | 0.53% | 30 |
|
|
2022
Q3 | $66.2M | Buy |
1,512,663
+82,082
| +6% | +$3.99M | 0.34% | 70 |
|
|
2022
Q2 | $75M | Buy |
1,430,581
+159,498
| +13% | +$8.13M | 0.4% | 59 |
|
|
2022
Q1 | $65.8M | Buy |
1,271,083
+123,492
| +11% | +$6.41M | 0.32% | 71 |
|
|
2021
Q4 | $67.8M | Buy |
1,147,591
+26,269
| +2% | +$1.3M | 0.32% | 71 |
|
|
2021
Q3 | $48.2M | Buy |
1,121,322
+141,066
| +14% | +$6.25M | 0.25% | 89 |
|
|
2021
Q2 | $38.4M | Buy |
980,256
+101,059
| +11% | +$3.93M | 0.22% | 109 |
|
|
2021
Q1 | $31.9M | Sell |
879,197
-15,314
| -2% | -$544K | 0.22% | 112 |
|
|
2020
Q4 | $32.9M | Buy |
894,511
+110,675
| +14% | +$4.06M | 0.25% | 101 |
|
|
2020
Q3 | $27.3M | Buy |
783,836
+72,182
| +10% | +$2.53M | 0.26% | 99 |
|
|
2020
Q2 | $22.1M | Sell |
711,654
-94,376
| -12% | -$3.21M | 0.23% | 97 |
|
|
2020
Q1 | $25M | Buy |
806,030
+264,339
| +49% | +$9.01M | 0.33% | 65 |
|
|
2019
Q4 | $20.1M | Buy |
541,691
+104,104
| +24% | +$3.71M | 0.25% | 92 |
|
|
2019
Q3 | $14.9M | Buy |
437,587
+126,071
| +40% | +$4.58M | 0.2% | 103 |
|
|
2019
Q2 | $12.8M | Buy |
311,516
+23,843
| +8% | +$947K | 0.18% | 102 |
|
|
2019
Q1 | $11.6M | Buy |
287,673
+123,959
| +76% | +$4.96M | 0.17% | 106 |
|
|
2018
Q4 | $6.78M | Buy |
163,714
+35,921
| +28% | +$1.49M | 0.12% | 123 |
|
|
2018
Q3 | $5.34M | Buy |
127,793
+9,077
| +8% | +$349K | 0.08% | 122 |
|
|
2018
Q2 | $4.09M | Sell |
118,716
-15,498
| -12% | -$530K | 0.07% | 132 |
|
|
2018
Q1 | $4.52M | Buy |
+134,214
| New | +$4.61M | 0.07% | 133 |
|
Other funds holding PFE
Rockefeller Capital Management's PFE Position: Q2 2026 in Review
Rockefeller Capital Management increased its Pfizer (PFE) stake by 0.42% in Q2 2026, buying an estimated $221K and bringing the position to 1,993,256 shares worth $48M. The position accounts for 0.07% of the portfolio, ranked #248.
Rockefeller Capital Management first reported a position in PFE in Q1 2018 and has held it in 34 quarters since. The position peaked at $106M in Q4 2022. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Rockefeller Capital Management held 1,993,256 shares of Pfizer worth $48M as of Q2 2026.
- Rockefeller Capital Management bought 8,430 Pfizer shares in Q2 2026, an estimated $221K.
- Pfizer made up 0.07% of Rockefeller Capital Management's portfolio in Q2 2026, its #248 holding.
- Rockefeller Capital Management first reported a position in Pfizer in Q1 2018 and has held it in 34 quarters since.
- Rockefeller Capital Management's Pfizer position peaked at $106M in Q4 2022.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.